awmsg logo



insulin glargine (Abasaglar®)


Reference No. 2307

Publication date:
10/12/2015


Appraisal information

insulin glargine (Abasaglar®) 100 units/ml solution for injection


Company: Eli Lilly & Co Ltd
BNF category: Endocrine system
NMG meeting date: 07/10/2015
AWMSG meeting date: 11/11/2015
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 3215
Ministerial ratification: 09/12/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Insulin glargine (Abasaglar®) is recommended as an option for restricted use within NHS Wales for the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above. Insulin glargine (Abasaglar®) should be prescribed within its licensed indication in accordance with NICE or AWMSG guidance for insulin glargine (Lantus®), the reference product. Insulin glargine (Abasaglar®) is not recommended for use within NHS Wales outside of these circumstances. Insulin glargine (Abasaglar®) should be prescribed by brand name to avoid automatic substitution and therefore help with pharmacovigilance.
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download